Navigation Links
Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
Date:3/11/2008

WESTFORD, Mass., March 11 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that President and Chief Executive Officer Michael Davin and Chief Financial Officer Tim Baker will present at the following institutional investor conferences in March:

-- On Monday, March 17, the Company will present at the Cowen and Company

28th Annual Health Care Conference, taking place at The Boston Marriott

Copley Place. The presentation will begin at 2:30 p.m. ET.

-- On Wednesday, March 19, Cynosure will present at the Citi Investment

Research 2008 Small and Mid-Cap Conference, taking place at the Four

Seasons at Mandalay Bay, Las Vegas. The presentation will begin at

1:45 p.m. ET.

These presentations will be available via live audio webcast and archived replay through the "Investor Relations" section of Cynosure's website, http://www.cynosure.com. To access the webcast, click on the link titled "Events."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd: YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

617.542.5300

cyno@investorrelations.com


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
2. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
3. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
6. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Lilly Announces Termination of AIR Insulin Program
9. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
10. Spectral announces 2007 financial results
11. Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
(Date:12/8/2016)... Worcester, Mass (PRWEB) , ... December 08, 2016 ... ... KbioBox genetic data bioInformatics portal. In response to client demand KbioBox developed a ... gene edit biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we ... of recovery so we need to do it well. Inadequate sleep levels have been ... blood pressure, stroke, diabetes, and even cancer. Maybe now is the best ... that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):